Followers | 101 |
Posts | 13186 |
Boards Moderated | 0 |
Alias Born | 06/01/2013 |
![](https://investorshub.advfn.com/uicon/401562.png?cb=1660063619)
Saturday, September 12, 2020 8:14:57 PM
Merck KGaA is extending its collaboration with Baylor College of Medicine to advance a manufacturing platform for the institute's potential vaccines against COVID-19.
The life science business of the German company, along with researchers at Baylor College and the Texas Children's Hospital Center for Vaccine Development will work to improve the manufacturing platform for CoV RBD219-N1, which is expected to enter clinical trials later this year. The potential vaccine was originally developed to target SARS.
The teams will also develop a new manufacturing platform for a second vaccine candidate to shorten the time to enter into phase 1 clinical trials.
Merck will help in large-scale manufacturing of the potential vaccines, the company said in a May 27 press release.
The company and the Texas Children's Center for Vaccine Development initially formed a partnership in 2018 to advance vaccine development and production to enhance the response to outbreaks.
Baylor College and Texas Children's Center for Vaccine Development are also collaborating with Swiss biotech Mymetics Corp. to create a potential COVID-19 vaccine.
As of May 28, there have been over 5.6 million confirmed cases of COVID-19 and more than 353,200 deaths due to the disease worldwide, according to Johns Hopkins University's Center for Systems Science and Engineering.
First time I've read them in the same article together yet it's still vague
Twas posted before ?
https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/merck-kgaa-teams-up-to-advance-baylor-college-s-potential-covid-19-vaccines-58809822
Principal company Partner company
Mymetics and Baylor College of Medicine to develop COVID-19 vaccines Baylor College of Medicine Mymetics Corp. Payment unspecified 5/18/20
European Vaccine Initiative to provide development services to Mymetics' CoV RBD219-N1 for COVID-19 infection European Vaccine Initiative Mymetics Corp. Payment unspecified 6/11/20
https://www.bioworld.com/biopharma-nonprofit-collaborations-2020
Recent MYMX News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 01/02/2024 06:16:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:00:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/13/2023 05:15:20 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 01:53:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 08:42:46 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 10/17/2023 07:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 01:00:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/18/2023 10:02:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2023 09:01:04 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM